Prospective, randomised and controlled examination of the successrate of an electrocardioversion with and without pretreatment

Prospective, randomised and controlled examination of the successrate of an electrocardioversion with and without pretreatment - ENCHANT – Establishing aN eleCtrocardioversion protocol witH ANd wiThout pretreatment

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

DRKS

Registry ID

DRKS00020900

Enrollment

100

Registered

2021-09-08

Start date

2021-09-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I48.1

Interventions

Group 1: electrocardioversion without pretreatment Group 2: electrocardioversion with pretreatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: patients with persistent and long persistent atrial fibrillation, who shall undergo an electrocardioversion

Exclusion criteria

Exclusion criteria: contraindication for a pharmaceutical pretreatment: o liver failure (transaminases AST and ALT exceeding three times of the upper limit) o hypersensitivity against the antiarrhythmic medication o severe kidney failure (eGFR 48h existing atrial fibrillation without a long anticoagulation or a exclusion of a thrombus via transesophageal echocardiogram (TEE) - patients with decompensated heart failure - patients with an active infection

Design outcomes

Primary

Measure	Time frame
Clinical comparison of two cardioversion protocols in successrate, lastingness, and side effects	—

Secondary

Measure	Time frame
Impact of the polymorphism of the beta1-adrenoreceptor on the successrate of the electrocardioversion.	—

Countries

Germany

Contacts

Public ContactEvren Caglayan

Universitätsmedizin Rostock, Zentrum für Innere Medizin, Abteilung Kardiologie

evren.caglayan@med.uni-rostock.de+49 381 494 7701

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026